The study investigates the effects of cannabidiol, a non-psychoactive component of marijuana, on psychotic symptoms in schizophrenia. Cannabidiol does not activate cannabinoid receptors but inhibits the degradation of the endocannabinoid anandamide. Previous research has shown that elevated anandamide levels in cerebrospinal fluid are inversely correlated with psychotic symptoms. The study conducted a double-blind, randomized clinical trial comparing cannabidiol to amisulpride, a potent antipsychotic, in acute schizophrenia patients. Both treatments were safe and effective, but cannabidiol had a better side-effect profile. Cannabidiol treatment significantly increased serum anandamide levels, which were associated with clinical improvement. The results suggest that inhibiting anandamide deactivation may contribute to the antipsychotic effects of cannabidiol, potentially providing a new mechanism for treating schizophrenia.The study investigates the effects of cannabidiol, a non-psychoactive component of marijuana, on psychotic symptoms in schizophrenia. Cannabidiol does not activate cannabinoid receptors but inhibits the degradation of the endocannabinoid anandamide. Previous research has shown that elevated anandamide levels in cerebrospinal fluid are inversely correlated with psychotic symptoms. The study conducted a double-blind, randomized clinical trial comparing cannabidiol to amisulpride, a potent antipsychotic, in acute schizophrenia patients. Both treatments were safe and effective, but cannabidiol had a better side-effect profile. Cannabidiol treatment significantly increased serum anandamide levels, which were associated with clinical improvement. The results suggest that inhibiting anandamide deactivation may contribute to the antipsychotic effects of cannabidiol, potentially providing a new mechanism for treating schizophrenia.